Global Osteoarthritis Therapeutics Market 2019-2023
SKU ID : TNV-14098795 | Publishing Date : 27-Mar-2019 | No. of pages : 125
Detailed TOC of Global Osteoarthritis Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Analgesics and NSAIDs - Market size and forecast 2018-2023
• Corticosteriods - Market size and forecast 2018-2023
• Viscosupplements - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Ankle osteoarthritis
• Hip osteoarthritis
• Knee osteoarthritis
• Shoulder osteoarthritis
• Others
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for osteoarthritis
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Analgesics and NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Analgesics and NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Corticosteriods - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Corticosteriods - Year-over-year growth 2019-2023 (%)
Exhibit 24: Viscosupplements - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Viscosupplements - Year-over-year growth 2019-2023 (%)
Exhibit 26: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Others - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bayer AG - Vendor overview
Exhibit 49: Bayer AG - Business segments
Exhibit 50: Bayer AG - Organizational developments
Exhibit 51: Bayer AG - Geographic focus
Exhibit 52: Bayer AG - Segment focus
Exhibit 53: Bayer AG - Key offerings
Exhibit 54: GlaxoSmithKline plc - Vendor overview
Exhibit 55: GlaxoSmithKline plc - Business segments
Exhibit 56: GlaxoSmithKline plc - Organizational developments
Exhibit 57: GlaxoSmithKline plc - Geographic focus
Exhibit 58: GlaxoSmithKline plc - Segment focus
Exhibit 59: GlaxoSmithKline plc - Key offerings
Exhibit 60: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 61: Johnson & Johnson Services, Inc. - Business segments
Exhibit 62: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 63: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 64: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 65: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 66: Pfizer Inc. - Vendor overview
Exhibit 67: Pfizer Inc. - Business segments
Exhibit 68: Pfizer Inc. - Organizational developments
Exhibit 69: Pfizer Inc. - Geographic focus
Exhibit 70: Pfizer Inc. - Segment focus
Exhibit 71: Pfizer Inc. - Key offerings
Exhibit 72: Sanofi - Vendor overview
Exhibit 73: Sanofi - Business segments
Exhibit 74: Sanofi - Organizational developments
Exhibit 75: Sanofi - Geographic focus
Exhibit 76: Sanofi - Segment focus
Exhibit 77: Sanofi - Key offerings
Exhibit 78: Validation techniques employed for market sizing
Keyplayers in Global Osteoarthritis Therapeutics Market 2019-2023
Bayer AGGlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Pfizer Inc.
Sanofi